900 related articles for article (PubMed ID: 30217172)
1. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study.
Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
BMC Neurol; 2018 May; 18(1):68. PubMed ID: 29751787
[TBL] [Abstract][Full Text] [Related]
3. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
Freedman MS; Brod S; Singer BA; Cohen BA; Hayward B; Dangond F; Coyle PK
J Neurol; 2020 Jan; 267(1):64-75. PubMed ID: 31559532
[TBL] [Abstract][Full Text] [Related]
4. Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon β-1a in the EVIDENCE study.
Coyle PK; Reder AT; Freedman MS; Fang J; Dangond F
J Neurol Sci; 2017 Aug; 379():151-156. PubMed ID: 28716230
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Sanford M; Lyseng-Williamson KA
Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977
[TBL] [Abstract][Full Text] [Related]
6. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
[TBL] [Abstract][Full Text] [Related]
7. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
Cohen BA; Rivera VM
Curr Med Res Opin; 2010 Apr; 26(4):827-38. PubMed ID: 20121658
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of daily high-dose vitamin D
Hupperts R; Smolders J; Vieth R; Holmøy T; Marhardt K; Schluep M; Killestein J; Barkhof F; Beelke M; Grimaldi LME;
Neurology; 2019 Nov; 93(20):e1906-e1916. PubMed ID: 31594857
[TBL] [Abstract][Full Text] [Related]
9. Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study.
Traboulsee A; Al-Sabbagh A; Bennett R; Chang P; Li DK; ;
BMC Neurol; 2008 Apr; 8():11. PubMed ID: 18426595
[TBL] [Abstract][Full Text] [Related]
10. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
11. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S
BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
[TBL] [Abstract][Full Text] [Related]
14. Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN.
Newsome SD; Scott TF; Arnold DL; Altincatal A; Naylor ML
Mult Scler Relat Disord; 2022 Jan; 57():103367. PubMed ID: 35158473
[TBL] [Abstract][Full Text] [Related]
15. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
16. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
[TBL] [Abstract][Full Text] [Related]
17. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
Kappos L; Havrdova E; Giovannoni G; Khatri BO; Gauthier SA; Greenberg SJ; You X; Wang P; Giannattasio G
Mult Scler; 2017 Nov; 23(13):1736-1747. PubMed ID: 28080250
[TBL] [Abstract][Full Text] [Related]
18. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
De Stefano N; Sormani MP; Stubinski B; Blevins G; Drulovic JS; Issard D; Shotekov P; Gasperini C
J Neurol Sci; 2012 Jan; 312(1-2):97-101. PubMed ID: 21880336
[TBL] [Abstract][Full Text] [Related]
20. Brain volume loss and no evidence of disease activity over 3 years in multiple sclerosis patients under interferon beta 1a subcutaneous treatment.
Rojas JI; Sanchez F; Caro F; Miguez J; Patrucco L; Funes J; Cristiano E
J Clin Neurosci; 2019 Jan; 59():175-178. PubMed ID: 30401571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
